Abstract / Summary
This meta-analysis aimed to evaluate the association between endometriosis (EM) and cardiovascular disease (CVD) risk by synthesizing evidence from large-scale cohort studies, with emphasis on subtype-specific risks and geographic disparities. We systematically searched PubMed, Embase, and Cochrane Library for cohort studies published until December 2024. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses stratified CVD subtypes (e.g. ischemic heart disease, atrial fibrillation), continents, and country development levels. Heterogeneity and publication bias were assessed via I2 statistics, sensitivity analyses, and Egger's test. Eleven cohort studies (n = 3,100,610 participants) were included. EM was associated with a 22% increased risk of all-cause CVD (HR = 1.22; 95% CI: 1.08-1.38; I2 = 94.6%). Subgroup analyses revealed elevated risks for myocardial infarction (HR = 1.29; 95% CI: 1.10-1.50), coronary artery disease (HR = 1.47; 95% CI: 1.29-1.67), and cerebrovascular events (HR = 1.18; 95% CI: 1.12-1.25), but not heart failure. Geographic disparities were significant, with higher CVD risks in Asian (HR = 1.36; 95% CI: 1.25-1.48) and North American cohorts (HR = 1.37; 95% CI: 1.16-1.61) compared to European populations (HR = 0.93; 95% CI: 0.64-1.34). EM is independently associated with an elevated risk of CVD, particularly for coronary artery disease and myocardial infarction. These findings underscore the need for targeted cardiovascular monitoring in EM patients, particularly in high-risk populations.
Primary Source
Annals of medicine
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.